Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Infectious Disease, Urology, Urinary Tract Infections |
| Therapuetic Areas: | Immunology / Infectious Diseases, Nephrology / Urology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | February 8, 2018 |
| End Date: | December 31, 2020 |
| Contact: | David Talan, MD |
| Email: | dtalan@ucla.edu |
| Phone: | 747-210-3107 |
Prevalence of Extended Spectrum β-lactamase and Carbapenem-Resistant Gram-Negative Bacteria in Patients With Urinary Tract Infection and Urosepsis Admitted Through Emergency Departments in the United States
Between 2013-2014, our study network of U.S. emergency departments, EMERGEncy ID NET, found
that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in
uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7%
of all cases, 2.6% in uncomplicated and 12.2% in complicated. More recently,
Enterobactericeae and gram-negative non fermenting bacteria have started to show resistance
to carbapenems (CREs and CR-NF). Patients hospitalized with UTI and urosepsis represent a
higher risk population for infections due to multi-drug resistant bacteria and experience
serious adverse outcomes, including death. EMERGEncy ID NET will conduct a study to determine
the prevalence of ESBL-producing, CREs and CR-NFs among this high risk population of patients
admitted for UTI from U.S. emergency departments.
that the rate of fluoroquinolone-resistant E. coli was 11.7% among all patients, 6.3% in
uncomplicated and 19.9% in complicated. ESBL-producing Enterobacteriaceae were found in 7.7%
of all cases, 2.6% in uncomplicated and 12.2% in complicated. More recently,
Enterobactericeae and gram-negative non fermenting bacteria have started to show resistance
to carbapenems (CREs and CR-NF). Patients hospitalized with UTI and urosepsis represent a
higher risk population for infections due to multi-drug resistant bacteria and experience
serious adverse outcomes, including death. EMERGEncy ID NET will conduct a study to determine
the prevalence of ESBL-producing, CREs and CR-NFs among this high risk population of patients
admitted for UTI from U.S. emergency departments.
Inclusion Criteria:
1. Age greater than or equal to 18 years;
2. Admitted to the hospital through the ED;
3. Primary reason for admission is treatment of UTI with or without sepsis (i.e., ED
diagnosis of UTI and/or sepsis); and
4. Provide verbal or written consent to participate in the study or if patient is unable
to provide consent (e.g., altered mental status), consent obtained from a legal
authorized representative.
Exclusion Criteria:
- patients will be later excluded if :
1. they are unable to provide a urine specimen for culture; or
2. their urine culture yields no growth or is contaminated (see definition of
positive urine culture below). Note: If participant's urine culture is
contaminated but their blood culture is positive for a uropathogen, they will not
be excluded.
We found this trial at
1
site
Click here to add this to my saved trials
